Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Efficacy of Cenv3 Peptide Vaccine for HCV
NCT01718834Phase 2Unknown
- Sponsor
- National Liver Institute
- Start
- Mar 2011
- Primary completion
- Mar 2013
- Modality
- Peptides, Recombinant Proteins and Enzymes, Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of IC41 in hepatitis C (HCV), sponsored by National Liver Institute. Status: unknown.
02
Drugs
IC41
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01718834.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01718834.